智通财经APP获悉,周五,Crinetics(CRNX.US)盘初暴涨23%,创8个月新高,报44.30美元。消息面上,此前FDA批准了其用于治疗肢端肥大症的药物,这是一种导致体内生长激素过多产生的罕见疾病。这种名为Palsonify的药物是一种每日一次的口服治疗药物,公司预计它将在十月初在美国上市。此次批准基于两项三期试验的数据,试验中药物耐受性良好,并带来了快速且一致的生化控制和症状减轻。
智通财经APP获悉,周五,Crinetics(CRNX.US)盘初暴涨23%,创8个月新高,报44.30美元。消息面上,此前FDA批准了其用于治疗肢端肥大症的药物,这是一种导致体内生长激素过多产生的罕见疾病。这种名为Palsonify的药物是一种每日一次的口服治疗药物,公司预计它将在十月初在美国上市。此次批准基于两项三期试验的数据,试验中药物耐受性良好,并带来了快速且一致的生化控制和症状减轻。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.